The Clinical Trial Recruitment Challenge: Why Trials Fail to Meet Enrollment Goals

Clinical trials are the engine of medical innovation, yet the systems supporting them can routinely undermine recruitment success.

Despite record investment, roughly 80% of clinical trials fail to meet their enrollment goals. Not because patients are unwilling to participate, or science is lacking, but because the clinical trial ecosystem remains fragmented and poorly aligned with how patients and physicians actually navigate care. 

This isn’t simply a logistical issue; it’s a human one, preventing patients with serious, often life-limiting conditions from being considered for relevant clinical research opportunities when time matters most. Notably, when trials can’t recruit efficiently, timelines extend, costs balloon, and the pace of medical progress slows.

The financial impact of these delays is staggering. According to a 2023 report by the Tufts Center for the Study of Drug Development, the average cost of bringing a new drug to market now exceeds $2.6 billion, with clinical trial delays being a major cost driver. Each day a trial is delayed can cost sponsors between $600,000 and $8 million.

Recruitment bottlenecks stem from three interconnected problems: limited resources at clinical trial sites, communication breakdowns across the trial ecosystem, and inefficient trial identification, pre-screening and matching processes. Each issue compounds the others, creating a cycle of inefficiency that impacts site staff, treating physicians, and most importantly, patients themselves.

Addressing this requires a multi-faceted approach that tackles these challenges in parallel, not in isolation. Purpose-built technology can improve screening accuracy through AI-powered matching, streamline fragmented referral workflows via unified platforms, and expand awareness of clinical trial opportunities through more comprehensive and connected trial networks.

The Pain Points

Clinical trial recruitment remains a major challenge, with 37% of trial sites under-enrolling for their research needs and one-third not enrolling anyone at all. 

Challenges begin at the relevant trial identification stage. Few platforms provide a complete overview of all clinical trials or investigational options, resulting in low awareness among both physicians and patients. Too often, this lack of visibility means potentially eligible patients are never informed about trials or learn about them when it is already too late. 

Simultaneously, public trial registries and databases (e.g. Clinical Trials, ISRCTN, CTIS) often contain outdated, incomplete or insufficiently actionable information, listing trials that are no longer recruiting or have changed their eligibility or requirement criteria. As a result, physicians and sites spend valuable time and resources reviewing patients that no longer meet current trial criteria, while patients face delays and uncertainty around potential participation.

Pre-screening remains a critical bottleneck in clinical trial recruitment. Sixty percent of US physicians surveyed report that existing pre-screening tools are either too complex or insufficient, leaving referral eligibility uncertain. As a result, referrals are delayed or never initiated at all, and patients miss narrow enrollment windows for trials they may have qualified for.

Fragmentation in the referral process further intensifies these delays. Referrals arrive through multiple decentralized channels, including professional networks, patient advocacy groups, messaging apps, and email, with no single system of record. Without a streamlined pathway, investigators are left managing disjointed workflows that slow coordination and weaken follow-through.

Left unaddressed, these challenges will become more acute as trials become increasingly complex and global, placing even greater strain on sites, physicians, and recruitment timelines.

The Technology Remedy

Technology has already brought significant improvements to the process of accessing information online about clinical trials and connecting patients to relevant trial sites.  However, many solutions remain point-based, leaving the broader trial journey only partially streamlined and inconsistently coordinated.

AI-powered tools are delivering tangible improvements in eligibility checks and pre-screening, enabling more efficient referrals and lowering screen failure rates at trial sites. Integrated with electronic health records, these tools can help identify potentially eligible patients within existing workflows, making pre-screening more timely and less burdensome for physicians and site teams. In fact, the NIH reported in 2024 that implementing AI-powered patient matching tools reduced their trial screening time by 40%, and some AI-powered matching tools have shown potential to significantly reduce the time physicians spend evaluating trial eligibility by up to 90%.

Once potential participants are identified, efficiency depends on how referrals are managed. Consolidating referrals from multiple sources into a single dashboard and standardizing secure communication between trial sites and physicians can reduce handoffs, minimize delays, and improve follow-through across the referral process. Registries and databases should provide up-to-date trial information across geographies to ensure physicians are aware of all possible options for their patients, including cross-border trials.

It is important to note that any technology in this space must meet rigorous standards. Data security and privacy compliance – guided by regulations such GDPR, HIPAA, ISO 27001, SOC 2 – aren’t optional. Trust is hard-won and easily lost, particularly when dealing with sensitive health information.

Alongside the role of technology itself, patient navigators – professionals who help patients and their loved ones understand trial intricacies and deal with logistics – are proven to increase enrollment rates, especially for underserved populations. Trial readiness is not defined by protocol eligibility alone. While AI-enabled pre-screening can identify patients who may qualify, patient navigators importantly help patients to determine whether participation is truly feasible and aligned with expectations, needs, and circumstances. This underscores an important nuance: while technological innovation is critical to combating the enrollment crisis, it must ultimately be combined with a human touch.

Trial Without Error

Reducing barriers to participation is essential to building a more effective and sustainable future for clinical trials and patients in need. Achieving this requires technologies that strengthen pre-screening and matching while remaining grounded in patient experience and site sustainability.

Clinical trial sites may benefit from tools that streamline communication across sponsors, sites, treating physicians, and patients, reducing friction and delays throughout screening, referral, and enrollment. At the same time, decision-makers must prioritize solutions that provide a complete and current view of relevant treatment options, improving awareness and access to emerging therapies.

It’s clear that the challenges associated with clinical trial recruitment also offer significant opportunities in terms of timely participation in relevant clinical research and crucial medical progress acceleration.